Research analysts at Zacks Research lowered their Q4 2026 EPS estimates for shares of Merck & Co., Inc. in a report released ...

AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Research analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of Merck & Co., Inc. in a research note issued to investors on Tuesday, April 1st. Zacks Research analyst S. Ganoria ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

According to Benzinga Pro, Merck & Co's peer group average for short interest as a percentage of float is 4.19%, which means ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co. has entered a ...